
PARKINSON'S DISEASE AND NEUROPSYCHIATRIC COMPLICATIONS

Dr Claire Hinnell

Fraser Health Movement Disorder Clinic

May 18, 2022



DISCLOSURES

- **I DO NOT** have an affiliation (financial or otherwise) with any for-profit or not-for-profit organizations



LEARNING OBJECTIVES

- Be able to describe common non-motor neuropsychiatric complications of Parkinson's disease.
- Understand the importance of addressing the following issues in Parkinson's disease and have an approach to treatment for them:
 - sleep disorders
 - cognition
 - psychosis
 - mood

IMPACT OF PD


Canada

100,000 (0.2% of adults in private households)

12500 residents of LTC homes have PD (4.9%)

Figure 2
Prevalence of Parkinson's disease in institutional population, by age group and sex, population aged 45 or older, Canada excluding territories, 2011/2012

percent



* significantly different from women ($p < 0.05$)

Source: Statistics Canada, CANSIM Table 105-1305.



OUTLINE

- Sleep
- Cognition
- Psychosis
- Mood

PARKINSON DISEASE

VISUAL SUMMARY OF RECOMMENDATIONS
FROM THE CANADIAN GUIDELINE FOR
PARKINSON DISEASE, 2ND ED

COMMUNICATION

- People with Parkinson disease should be encouraged to participate in choices about their own care.
- Communication should be in verbal and written form.
- Discussions should aim to achieve a balance between providing realistic information and promoting optimism.
- Families and caregivers should be informed about the condition and available support services.



DIAGNOSIS AND PROGRESSION

- Parkinson disease should be suspected in anyone with tremor, stiffness, slowness, balance problems or gait disorders.
- CT or MRI brain scanning should not be routinely used to diagnose Parkinson disease.
- Patients, especially young, who request genetic testing should be assessed by a movement disorders specialist.
- No therapies are effective for slowing or stopping brain degeneration in Parkinson disease.



PALLIATIVE CARE

- The palliative care needs of people with Parkinson disease should be considered throughout all phases of the disease.
- If the patient asks, the option of medical assistance in dying should be discussed.



TREATMENT

- Levodopa is the most effective medication and may be used early.
- A regular exercise regimen begun early has proven benefit.
- Patients with possible diagnosis of Parkinson disease may benefit from a trial of dopamine replacement therapy to help with diagnosis.
- Impulse control disorders can develop on dopaminergic therapy at any stage in the disease but are more common in patients on dopamine agonists.
- Deep brain stimulation and gel infusion are now routinely used to manage motor symptoms.
- Rehabilitation therapists experienced with Parkinson disease can help newly diagnosed patients, and others through all stages.



NONMOTOR FEATURES

- Botulinum toxin A helps control drooling.
- Drug therapy for low blood pressure includes midodrine, fludrocortisone and domperidone.
- Management of depression should be tailored to the individual and their current therapy.
- Dementia should not exclude a diagnosis of Parkinson disease, even if present early.
- Rapid eye movement sleep behaviour disorder can pre-date the diagnosis of Parkinson disease.



PD SYMPTOMS



NON-MOTOR SYMPTOMS

Autonomic

- orthostatic hypotension
- urinary urgency/frequency
- constipation
- erectile dysfunction
- temperature dysregulation

Neuropsychiatric

- sleep
- RBD
- depression, anxiety
- apathy
- cognitive impairment
- psychosis

NEUROPSYCHIATRIC COMPLICATIONS OF PD

Intrinsic to PD

- depression
- anxiety
- apathy
- impaired executive function
- subcortical dementia
- RBD
- akathisia
- anhedonia

Associated with dopaminergic therapy

- hallucinations
- paranoia
- delusions
- ICD
- compulsive behaviours
- delirium
- dopamine dysregulation syndrome

MAJOR MEDICATION CLASSES

****DOPAMINE****

Levodopa-carbidopa

Levodopa-benserazide

DOPAMINE AGONISTS

Pramipexole

Ropinirole

Rotigotine patch

Bromocriptine

MAOB-I

Rasagiline

Selegiline

ADD-ON MEDICATIONS

COMT-I

Entacapone

Amantadine

MAOB-I

Rasagiline

Selegiline

**Anti-
cholinergics**


Trihexyphenidyl





PD MEDS – TIMING IS EVERYTHING

- routine is key
- missed or delayed doses have significant deleterious effects on patient in that moment and rest of the day
- not acceptable to delay or miss (eg: patient napping)
 - if meds interfere with sleep regularly, we can adjust schedule
- acceptable window is maximum 15 minutes
- requires policy change for nursing staff
- allow patients to administer if appropriate





"No wonder you have insomnia . . .
lying there awake all night."

BENEFIT OF GOOD SLEEP IN PD



- better quality of life ratings
- improved mood
- clearer cognition
- reduced severity of daytime parkinsonism
- reduced daytime sleepiness

SLEEP IN THE OLDER PERSON






SLEEP PROBLEMS IN PD


- more fragmented than in same age without PD
- difficulty sleeping through the night
- difficulty getting back to sleep
- may get to sleep but wake after a few hours
- can get reversal of sleep-wake cycle with sundowning




PATIENT EXPERIENCE

- 75 yo gentleman reported trouble sleeping
- his legs started bothering him later in the evening and he had to walk around for 20-30 minutes til they felt better and he could finally get to sleep
- he woke up several times a night and had trouble getting back to sleep
- he woke up unrefreshed in the morning and struggled through til mid morning when he finally ‘got going’
- he had a nap in the later afternoon as he couldn’t make it til bedtime
- he was becoming more irritable and having problems with his short term memory







Cognitive
issues

Motor
symptoms

Mood
disorders



Autonomic
problems

Sleep
disorders

Poor
sleep
in PD



Drug side
effects

SLEEP DISORDERS






SLEEP DISORDERS




MOTOR SYMPTOMS




- cramps
- stiffness, difficulty rolling
- akathisia, restless
- treatment
 - bedtime levodopa (CR)
 - overnight levodopa
 - cautiously rotigotine patch (but not if any cog issues)

AUTONOMIC PROBLEMS



- Urination issues
 - minimize drinking liquids x 3 hours before bed
 - go to bathroom right before sleep
 - commode or urinal (reduce effort, arousal, light)
 - condom catheter
 - medications to reduce frequency (solifenacin, mirabegron)
 - avoid centrally acting anticholinergics
 - urologist referral
- Temperature dysregulation
 - behavioural (change sheets, frequent baths, light clothing/bedding)

DRUG SIDE EFFECTS



- Levodopa-carbidopa and dopamine agonists
 - sleep attacks
 - daytime sleepiness
 - can be alerting at bedtime
 - provoke vivid dreams
- Medication review
 - mirtazapine, SSRIs can worsen RBD

DAYTIME SLEEPINESS

- excessive daytime somnolence
 - Parkinson's disease itself (more in advanced PD and those with cognitive impairment)
 - sleep disturbance at night
 - drug side effects – dopamine, anti-depressants, sedatives
- stimulants
 - careful in elderly
 - controversial



PATIENT EXPERIENCE

- his legs started bothering him in the evening, had to walk around for 20-30 minutes
 - **RESTLESS LEGS** – started low dose gabapentin cautiously
- he woke up several times a night and had trouble getting back to sleep
 - **URINARY FREQUENCY** - reduced fluid intake, had prostate checked, tried solifenacin
 - **ANXIETY** mindfulness exercises before bed
- awoke unrefreshed and struggled through til mid morning when he finally ‘got going’
 - **DRUG SIDE EFFECT (eg: taking high dose of mirtazapine at bedtime)** reduced bedtime dose of mirtazapine
 - **RBD** - tried melatonin
- he had a nap the later afternoon as he couldn’t make it til bedtime
 - **BEHAVIOURAL-** moved nap earlier and made it shorter
- he was becoming more irritable and have problems with his short term memory
 - **CAUSED MOOD AND COGNITIVE SYMPTOMS**
- Overall improvement in sleep and physical symptoms




TIPS AND TRICKS

- satin sheets and pjs to make moving in bed easier
- keep regular sleep schedule
- bedtime routine – keep same
- get outside everyday and exercise, in morning, avoid evening
- if nap, same time every day, < 1 hr, not after 3pm
- avoid stimulants
- alcohol can disrupt sleep
- avoid heavy evening meals
- sleep in cool dark room
- bed for sleep and sexual activity only
- avoid screen time later in evening



SUMMARY

- Sleep is a common problem in Parkinson's disease
- Untreated it can significantly affect quality of life
- Detective work is needed to break the problem down to find the contributing causes that can be treated



NEUROPSYCHIATRIC COMPLICATIONS OF PD

Intrinsic to PD

- depression
- anxiety
- apathy
- **impaired executive function**
- **subcortical dementia**
- RBD
- akathisia
- anhedonia

Associated with dopaminergic therapy

- hallucinations
- paranoia
- delusions
- ICD
- compulsive behaviours
- delirium
- dopamine dysregulation syndrome

COGNITION IN PD


- at time of diagnosis, 30% have mild cognitive impairment
- about 40-80% of people with PD develop dementia
- not everyone with PD experiences dementia
- **slow ≠ cognitively impaired**
- DO NOT diagnosis patient with new onset cognitive symptoms as dementia – very likely delirium = REVERSIBLE condition




COGNITIVE IMPAIRMENT



- does NOT mean patient has DLB
 - Fluctuations in cognition with pronounced changes in attention/alertness
 - Recurrent visual hallucinations
 - REM behavior disorder
 - ≥ 1 spontaneous features of parkinsonism
- different Dx and prognosis
- neuroleptic sensitivity
- if develop cog issues at same time as parkinsonism – think DLB (< 1 year)
- if develop parkinsonism and then some time later start to develop dementia – think PDD (mean 10 years)
- DO NOT diagnosis hospitalized patient with new cognitive symptoms as dementia – very likely delirium = REVERSIBLE condition



APPROACH TO COGNITIVE IMPAIRMENT IN PD



SPECIFIC MEDICATION TX OF COGNITION

- medications – play a small role overall
- indicated for mild to moderate dementia
- rivastigmine is the only one FDA-approved to treat PDD
- Canadian guidelines:
 - can use rivastigmine or donepezil for PD dementia
 - can consider using galantamine for PD dementia (if not responding or side effects on the others)
 - s/e: nausea, diarrhea, orthostasis
 - not recommended if heart block, syncope or significant bradycardia
 - memantine can be added or substituted if cholinesterase inhibitors are not tolerated or lack efficacy



COGNITIVE IMPAIRMENT

The diagnoses of dementia associated with PD and of mild cognitive impairment in PD can be made using the Movement Disorder Society Clinical Diagnostic Criteria. These require reports of subjective cognitive decline and difficulties on psychometric testing.

CAN

GPP

For PD dementia, cholinesterase inhibitors could be added: rivastigmine (grade: A), donepezil (grade: A), or galantamine (grade: C). There may be idiosyncrasy in clinical response and adverse effects, so it is worth trying an alternative agent (grade: GPP). Memantine can be added or substituted if cholinesterase inhibitors are not tolerated or lack efficacy (grade: C).

EFNS¹⁴

Varied

No interventions have been proven to reduce the risk of progression of PD from mild cognitive impairment to dementia but lifestyle modifications, such as engaging in cognitive and social activities and physical exercise, are encouraged.

CAN

GPP

cholinesterase inhibitor

NEUROPSYCHIATRIC COMPLICATIONS OF PD


Intrinsic to PD

- depression
- anxiety
- apathy
- impaired executive function
- subcortical dementia
- RBD
- akathisia
- anhedonia

Associated with dopaminergic therapy

- **hallucinations**
- **paranoia**
- **delusions**
- ICD
- compulsive behaviours
- delirium
- dopamine dysregulation syndrome

PSYCHOSIS IN PD





PSYCHOSIS - CAUSES

Patient factors

- cognitive decline
- sleep deprivation
- other medical condition (delirium)
- depression
- advanced age

Due to med side effect

- dopaminergic medications
- use of adjunctive PD tx
- multiple PD meds
- concomitant use of other psychoactive meds



PSYCHOSIS APPROACH

Non-medication

- lighting
- redirect
- sleep
- safety – weapons etc.

Medication

- review polypharmacy
- consider taper and stop, in order:
 - anti-cholinergics
 - amantadine
 - dopamine agonists
 - entacapone
 - MAOB inhibitors (rasagiline, selegiline)
- adjust levocarb-cautious, consult

PSYCHOSIS

- Treatments:
 - Cholinesterase inhibitors
 - Quetiapine
 - Clozapine – FDA approved in PD
 - Pimavanserin – FDA approved in PD (not in Canada yet)




Table 1: Parkinson's disease psychosis and antipsychotic use

Commonly Used in PDP	
Clozapine	Improves psychosis without worsening PD symptoms; may cause agranulocytosis therefore requires specialized monitoring ³⁸⁻⁴⁰
Quetiapine	Most commonly used, inconsistent efficacy but no worsening of PD symptoms ^{40,42-45}
Should Not Be Used in PDP	
All typical antipsychotics	Significant worsening of PD symptoms ²⁴
Aripiprazole	Inconsistent efficacy and worsening of PD symptoms ²⁵⁻²⁷
Olanzapine	No efficacy and worsening of PD symptoms ²⁸⁻³⁰
Risperidone	Some efficacy but worsening of PD symptoms ³¹⁻³⁵
Ziprasidone	Insufficient evidence for efficacy and tolerability, but has limited use due to cardiac side effects and should be avoided ^{36,37}

PD = Parkinson's disease; PDP = Parkinson's disease psychosis

All people with PD and psychosis should receive a general medical evaluation and treatment for any precipitating condition.

NICE⁷

D
GPP

For patients with PD and psychosis, polypharmacy should be reduced.

EFNS¹⁴

GPP

- Anticholinergic antidepressants should be reduced or stopped; anxiolytics or sedatives should be reduced or stopped.
- Antiparkinsonian drugs should be reduced. Anticholinergics should be stopped, amantadine should be stopped, dopamine agonists should be reduced or stopped, MAO-B and COMT inhibitors should be reduced or stopped and, lastly, levodopa should be reduced.

Hallucinations and delusions should not be treated if they are well tolerated by the person with PD and their family members and caregivers (as appropriate). Even minor hallucinations or delusions should be considered a marker of disease progression, and should warrant a general medical evaluation and treatment for any precipitating factors.

NICE⁸

GPP

For patients with PD and psychosis needing treatment:

- Quetiapine is possibly useful.
- Clozapine is useful but requires monitoring.

EFNS¹⁴

GPP

EFNS¹⁴

A

With the exception of quetiapine and clozapine as described in recommendation C90, all other antipsychotics should be avoided in PD psychosis (grade: GPP). Olanzapine (grade: A), risperidone (grade: C) and aripiprazole (grade: GPP) can worsen parkinsonism (harmful).

EFNS¹⁴


Varied

Pimavanserin could be considered as a treatment for PD psychosis.

CAN

B

Figure 1. Clinical symptoms and time course of Parkinson's disease³



EDS = excessive daytime sleepiness; MCI = mild cognitive impairment; RBD = rapid eye movement sleep behavior disorder. Reproduced with permission from Kalia et al., 2015.³



NEUROPSYCHIATRIC COMPLICATIONS OF PD

Intrinsic to PD

- **depression**
- **anxiety**
- **apathy**
- **anhedonia**
- impaired executive function
- subcortical dementia
- RBD
- akathisia

Associated with dopaminergic therapy

- hallucinations
- paranoia
- delusions
- ICD
- compulsive behaviours
- delirium
- dopamine dysregulation syndrome

MOOD IN PARKINSON'S

- Depression - up to 60%
- Anxiety - 25-45%
- Apathy



- Premotor for some patients

- Increased risk:
 - Women > men
 - Advanced stage of PD
 - Patients with cognitive problems

- **PD symptom most correlated with poor quality of life

- Can affect long-term outcomes by causing social withdrawal, lack of exercise, more reluctant to seek care

MOOD IN PARKINSON'S



Orienting/Emotion Identification
Automatic Emotion Regulation
Voluntary Emotion Regulation
Regions Implicated in Both Automatic and Voluntary Emotion Regulation



MOOD IN PARKINSON'S

Depression

- Persistent sad, anxious, or “empty” mood
- Feelings of hopelessness or pessimism
- Feelings of guilt, worthlessness, helplessness
- Loss of interest or pleasure in hobbies or activities, especially those which were previously enjoyable
- Decreased energy or fatigue
- Difficulty concentrating, remembering, and making decisions
- Difficulty sleeping, early-morning awakening or oversleeping
- Appetite and/or weight changes
- Thoughts of death or suicide
- Restlessness, irritability
- Persistent physical symptoms

Anxiety

- Restlessness, feeling wound-up or on edge
- Fatigue
- Difficulty concentrating or having their minds go blank
- Irritability
- Muscle tension
- Difficulty controlling the worry
- Sleep problems, such as difficulty falling or staying asleep, or restless or unsatisfying sleep

MOOD- TREATMENT

Medications


- SSRI
- SNRI
- TCA – generally avoid
- Other atypical antidepressants:
 - Bupropion (Wellbutrin) – increases norepinephrine and dopamine activity. Most activating antidepressant. Least likely to cause sexual side effects.
 - Mirtazepine (Remeron) – enhances release of norepinephrine and serotonin by different mechanism. Can stimulate appetite and improve sleep
- Others for anxiety
 - benzos – avoid – sedation, risk dementia
- MAOB-I interactions

Non-medications

- exercise
- CBT
- social activities
- support groups
- review PD – can have ‘off’ anxiety
- Other interventions – relaxation techniques, biofeedback, meditation, massage, acupuncture, aromatherapy

INTERVENTIONS FOR MOOD

- Electroconvulsive Therapy:
 - Electric current applied through the scalp
 - Effective in severe or refractory depression
 - May also help motor symptoms
 - Drawbacks – requires general anesthesia, temporary confusion and/or short-term memory problems.
- Repetitive transcranial magnetic stimulation (rTMS)
 - Non-invasive coils to produce magnetic pulses that stimulate specific brain regions




PSEUDOBULBAR AFFECT

- brief episodes of emotional lability that do not match a person's feelings or situation
- uncontrollable or inappropriate laughing or crying
- frequently mistaken for depression
- due to damage to brain areas that control normal expression of emotion
- can cause stress or frustration or avoidance of social interaction
- Treatment:
 - education, understanding
 - SSRI



APATHY

- can occur by self or co-occur with depression or cognitive impairment
- Cognitive/Behavioral:
 - Little or no-goal directed behavior, inability to “get up and go”
 - Trouble initiating activities/tasks, needs to be prompted
 - Loss of curiosity in learning new things
- Emotional:
 - Emotional indifference or inability to express emotion
 - Lack of passion related to activities or situations that previously provoked emotion
 - Less empathy toward feelings of others
- Social:
 - Less interest in participating in social or leisure activities
 - Less interest in family or interest in meeting new people
 - Less participation in conversation
 - Reduced spontaneous interactions with others





APATHY - TREATMENT

- Treatment – no approved therapies
- Maintain a regular schedule of structured activities:
 - Focus on more relevant activities first – medical and therapy appointments
 - Chores, household duties
 - Keep a calendar and check tasks off as they are done
- Avoid isolation:
 - Schedule time with family and friends
 - Support groups
- Tips for caregivers:
 - Be patient
 - Provide positive feedback when goals are reached



TAKE HOME MESSAGES

- Medication
 - changes across the spectrum
 - watch for medication side effects that can affect motor or non-motor aspects of PD
 - do NOT stop levocarb
 - *****medication timing*** - consider institutional policy**
- Sleep – multifactorial, need to be a detective
- As cognition declines and/or psychosis develops, review PD and non-PD medications
- Mood - #1 cause of poor quality of life in PD and is treatable
- If in doubt, please ask: movement disorder RACE app

THANK YOU

